Marras Carlos, Monteagudo Indalecio, Salvador Georgina, de Toro Francisco J, Escudero Alejandro, Alegre-Sancho Juan J, Raya Enrique, Ortiz Ana, Carmona Loreto, Mestre Yvonne, Cea-Calvo Luis, Calvo-Alén Jaime
Hospital Universitario Virgen de Arrixaca, Calle Polideportivo, 5, 30120, Murcia, Spain.
Hospital Universitario Gregorio Marañón, Madrid, Spain.
Rheumatol Int. 2017 Jul;37(7):1195-1202. doi: 10.1007/s00296-017-3737-y. Epub 2017 May 17.
The ARCO study (Study on Adherence of Rheumatoid Arthritis patients to SubCutaneous and Oral Drugs), a multicenter, non-interventional retrospective study, was primarily designed to assess the percentage of patients [aged ≥18 years with an established rheumatoid arthritis (RA) diagnosis] with non-adherence to prescribed subcutaneous biologicals. This paper reports data for the secondary objective from a subset of patients, namely to evaluate non-adherence to prescribed oral antirheumatic drugs in RA patients in Spain using the validated Compliance Questionnaire Rheumatology (CQR). Patients also completed the Morisky-Green Medication Adherence Questionnaire, Beliefs about Medicines Questionnaire, and a questionnaire (developed and validated in Spain) on patient satisfaction with RA treatment and preferences. A total of 271 patients (76.7% females; mean age 55.6 years) were being treated with oral drugs for RA, of which 234 completed the CQR questionnaire. Non-adherence was reported in 49/234 (20.9%) patients. The proportion of non-adherence in younger patients (aged ≤48 years; 37.5%) was double that recorded in patients aged >48 years (p = 0.006). Patients with a perception of lower efficacy also had a higher risk of non-adherence (p = 0.012). Multivariable analysis showed that younger age and male gender were independently associated with risk of non-adherence. There was only slight agreement between the CQR and Morisky-Green assessment tools (kappa coefficient = 0.186), possibly reflecting the fact that both questionnaires measure slightly different aspects of medication adherence. In conclusion, one out of five RA patients was identified as at risk for non-adherence with the CQR, and this was more frequent in younger patients and in males.
ARCO研究(类风湿关节炎患者皮下及口服药物依从性研究)是一项多中心、非干预性回顾性研究,其主要目的是评估确诊为类风湿关节炎(RA)且年龄≥18岁的患者中未遵医嘱使用皮下生物制剂的比例。本文报告了部分患者的次要目标数据,即使用经过验证的类风湿关节炎依从性问卷(CQR)评估西班牙RA患者未遵医嘱使用口服抗风湿药物的情况。患者还完成了Morisky - Green药物依从性问卷、药物信念问卷以及一份关于患者对RA治疗满意度和偏好的问卷(在西班牙开发并验证)。共有271例接受RA口服药物治疗的患者(女性占76.7%;平均年龄55.6岁),其中234例完成了CQR问卷。49/234(20.9%)例患者报告存在不依从情况。年轻患者(年龄≤48岁;37.5%)的不依从比例是年龄>48岁患者的两倍(p = 0.006)。认为疗效较低的患者不依从风险也更高(p = 0.012)。多变量分析表明,年龄较小和男性与不依从风险独立相关。CQR和Morisky - Green评估工具之间仅有轻微一致性(kappa系数 = 0.186),这可能反映出两份问卷测量的药物依从性方面略有不同。总之,五分之一的RA患者被确定存在使用CQR评估的不依从风险,且在年轻患者和男性中更为常见。